# Intermittent Liposomal Amphotericin B Primary Prophylaxis

> **NCT00451711** · PHASE2 · UNKNOWN · sponsor: **Bayside Health** · enrollment: 60 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Liposomal amphotericin B

## Key facts

- **NCT ID:** NCT00451711
- **Lead sponsor:** Bayside Health
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-05
- **Primary completion:** —
- **Final completion:** 2014-10
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2013-12-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00451711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00451711, "Intermittent Liposomal Amphotericin B Primary Prophylaxis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00451711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*